



Protection & Connectivity to ALL Injection Devices for Home Care Wearables & AI Platforms

TEMPRAMED INTRODUCTION · Sep 2026



www.tempramed.com



As Seen On
DR. PHIL



Medication reminder & temperature protector

The opportunity — 4 mega trends converge on connected, temperature-protected injectables

Each one independently expands demand for protected, connected injectable medication.

01 THE GLP-1 & PEPTIDE BOOM

Weight-loss injectables becoming a mass market.

▲ Hundreds of millions now carry an injectable pen every day.

02 CARE IS MOVING INTO THE HOME

Treatment is leaving the clinic to Home-Care.

▲ Responsibility moves from the HCP to the patient.

03 DIGITAL HEALTH & WELLNESS SCALE UP

Explosion of wearable medical devices and AI medical platforms

▲ Every platform is hunting for new clinical signals to own.

04 EXTREME HEAT BECOMES A MEDICAL RISK

Increasing number of temperature extremes events

▲ Last-mile protection moves from convenience to necessity.

WHY TEMPRAMED GAINS FROM ALL FOUR

The only platform that combines a validated temperature shield with pen-agnostic smart connectivity.

1 A larger market with every launch

Each new GLP-1, insulin or biologic user is another pen to protect and connect.

2 Home care needs the last mile

As therapy moves home, protection becomes the patient's problem — and our product.


3 Recurring digital-health revenue

Device sales plus subscription data revenue as connected therapy becomes the standard.

TempraMed owns unique solutions for future digital health platforms

SOURCES · GLP-1: Lilly FY2026 guidance \$82–85B and ~60% category share (CNBC, Feb 2026); Novo oral Wegovy >3M prescriptions in five months (2026) · Home care: home infusion therapy \$52.2B (2026) → \$97.7B (2035), Towards Healthcare · Digital health: digital health & wellness ~\$494B (2026) at ~18.9% CAGR, Business Research Insights; 562.9M smartwatch users (2025) → 740.5M (2029), 92% tracking health · Heat: Western Europe hottest June on record, +3.06°C vs 1991–2020, 1,300+ excess deaths (Copernicus / WMO, 2026); MHRA guidance on insulin and refrigerated medicines in extreme heat.

The winning platform needs VIVI by TempraMed for injectables



SOURCES · Oura & LillyDirect partnership, 23 Jun 2026 (ouraring.com / MM+M) · WHOOP Series G \$575M at \$10.1B with Abbott as strategic investor, 31 Mar 2026 (businesswire.com / MedTech Dive) · Samsung completes Xealth acquisition, 17 Oct 2025 — 500+ hospitals (news.samsung.com / Fierce Healthcare) · Withings joins Novo Nordisk Partner Platform, 2026 (withings.com).

What is TempraMed?

TempraMed's products are essential for hundreds of millions of injection pens and vials used every day — providing hassle-free temperature shield and data connectivity.

150,000~ UNITS SOLD



Advanced temperature protection and injection reminders for injectable medications.

- ✓ Compact, made in USA, FDA-registered, validated smart thermal shield
- ✓ Zero maintenance: no charging for the thermal shield
- ✓ Protection that works 24/7/365 for years (2-year warranty)
- ✓ Fits all major pens & vials: insulin, Ozempic, GLP-1, EpiPen & biologics
- ✓ Automatic dose capture & medication reminder, app connectivity for RPM systems

Unique patented & validated technology platform

Combining features used in spacecraft, avionics and medical cryotherapy.

1 Proprietary thermal structure – 11 granted patents

Patented architecture engineered around the medication cartridge.

2 Exceptional “space-grade” thermal insulation

Insulation class used where failure is not an option.

3 Monitoring, controlling and tracking electronics

Continuous temperature sensing and dose telemetry.

4 Self-reactivated heat-absorbing material

Regenerates on its own: no charging, no ice packs, no water.



Hassle-free, lightweight products that maintain the proper temperature of injectable medications for years — without maintenance or any external energy source.

Existing product portfolio



VIVI Cap

The core original product providing validated temperature protection for insulin pens without electricity or batteries.

- ✓ 24/7 temperature shield
- ✓ Maintenance free
- ✓ Fit & forget design



VIVI Cap Smart

Next-generation connected device integrated with a mobile app and subscription model for enhanced patient monitoring.

- ✓ Real-time temp monitoring
- ✓ App connectivity
- ✓ Subscription revenue



VIVI Med

Expanded protective solution designed for vials, biologics, GLP-1 therapies and temperature-sensitive test strips.

- ✓ Fits standard vials
- ✓ Covers GLP-1s / biologics
- ✓ Protects test strips



VIVI Epi

Expanded marketing initiative for epinephrine auto-injector protection, addressing critical allergy markets.

- ✓ EpiPen compatible
- ✓ Critical heat protection
- ✓ Life-saving reliability

VIVI “Smart” platform for digital health

Launched December 2025 — from hardware to a recurring data layer.

VIVI smart devices protect medications and harness data analysis, enabling remote management of medical conditions and adherence to therapy.

AUTOMATIC TRACKING

VOICE RECOGNITION

APP CONNECTIVITY

01

Automatic injection capture

Pen-use detection records every injection without patient input.

02

Voice dose recognition

Voice or discreet keypad insertion for creating a full record.

03

Real-time alerts and data analytics

Temperature and adherence signals surfaced as they happen.

04

Health & Wellness Management integration

Connects with Apple Health™ & Google Fit®.



Play the VIVI Cap Smart video
vimeo.com



SCAN TO WATCH

Product portfolio: new products

Making every injection device connected and temperature protected.



VIVI Med Smart

Temperature shield and connectivity for medication injectors and vials.



VIVI Cool 8c

Hassle-free keeping of medications refrigerated for up to 24 hours.



VIVI Box / VIVI Box8c & Smart versions

Hassle-free room-temperature or fridge box for multiple injectors and vials.

CONTROL & MANAGEMENT

Transferred into the hands of the patients

LIFE SAVING

Poor control and storage of medications causes damage, resulting in loss of lives

SAFETY

Medications are protected for years

MAINTENANCE


No maintenance, batteries or charge is required

COMPLIANCE

Medications safely with them all the time; patients avoid dosage non-compliance

Path to reimbursement - healthcare savings for payors

US base case · diabetes example



Severe event reduction DKA prevention (\$29,981/event) & severe hypoglycemia (\$1,700/event)	\$890
HbA1c improvement \$1,100 saved per 1% HbA1c reduction (better medication efficacy)	\$550
Anxiety & utilization Reduced doctor / ER visits & anxiety costs (baseline \$1,684/year)	\$525
Medication waste Prevention of temperature degradation = fewer replacements	\$260

HEALTHCARE UTILIZATION IMPACT

2–3 ER visits avoided / year	2–3 Doctor visits reduced / year	0.5–1 Hospital days saved / year
--	--	--

NET ANNUAL ROI CALCULATION

Total annual savings	\$2,225
Device net cost (after copay)	–\$80
Net annual ROI per patient	\$2,145

\$2.2M–\$4.5M
Per 1,000 patients, per year and 2 years

Source: company interactive payor model, US base case, diabetes case.

**Run the interactive model**
Adjust the assumptions live



Demand is already there — Ready to Scale

Six-figure installed base, an active user record, and four independent routes to market — no single-channel dependency.

150,000+

Devices sold

200,000+

Insulin users on record

Four independent routes to market

Each channel can scale on its own — no dependence on any single partner or geography.

PAYORS & HEALTH SYSTEMS

HMOs and insurers adopting on validated ROI



PHARMACY & RETAIL

National chains and pharmacy networks



DISTRIBUTION & WHOLESALE

Distributors across the Gulf and Latin America



CLINICAL & ADVOCACY

Clinician recommendation and education networks



Commercial risk is spread across four channels that can each scale independently.

Why TempraMed Will own this category

Only validated solution

No other product addresses the “last-mile” storage gap. TempraMed owns the patent on this space-grade insulation technology.

Zero maintenance burden

Competitors require ice packs, charging or water activation. VIVI Cap is “set and forget” — no patient effort required.

Medication reminder with smart app connectivity

App for dose capturing, with onboard display of time since last injection.

Clinical credibility

FDA & CE registered. Endorsed by experts from Yale School of Medicine and ADCES educators.

FEATURE · COMPETITIVE LANDSCAPE	VIVI CAP	TRADITIONAL COOLERS
Years of 24/7/365 protection without maintenance	✓	X
Medication reminder & app connectivity	✓	X
Pocket size	✓	X
Years of life	2+ years	Varies
FDA registered	✓	—
Patient compliance	High (>90%)	Low (<30%)

PROVEN ECONOMIC VALUE

3x–30x ROI

Break-even < 3 months

100,000+

TRUSTED USERS

4.8 / 5

AVERAGE RATING

3–30x

PROVEN ROI

< 3 mo

BREAK-EVEN

One universal layer under every injectable — no one else can say that

Every existing smart-pen solution is welded to one brand's pen. VIVI is the only layer built for any pen, any vial, any auto-injector — plus the temperature shield none of them have.

TODAY — FRAGMENTED, BRAND-LOCKED, CONNECTIVITY ONLY

NOVO NORDISK	SANOFI	ELI LILLY	BIOCORP · GOCAP · INPEN
own smart pen	own smart pen	own smart pen	independent smart caps
 Its own pen, one brand	 Its own pen, one brand	 Its own pen, one brand	 Its own pen, one brand
 Other pens, vials, EpiPen	 Other pens, vials, EpiPen	 Other pens, vials, EpiPen	 Other pens, vials, EpiPen
 Temperature shield	 Temperature shield	 Temperature shield	 Temperature shield

WITH VIVI — ONE LAYER, ANY BRAND, ANY FORM FACTOR


VIVI BY TEMPRAMED				
The universal shield + data layer				
	Any pen, any brand	Vials & biologics	GLP-1 & auto-injectors	Temperature shield 24/7/365
	✓	✓	✓	✓

Every incumbent is locked to one brand's pen. VIVI is the only layer built to fit all of them.


Current platform tracks everything — except the injectables

Injectable medication use and integrity is the one clinical signal no wearable, ring or CGM can capture on its own. VIVI already closes it — for any pen, any vial, any brand.

WHAT PLATFORMS ALREADY SEE



WITH VIVI — THE GAP CLOSSES



BUILD IT YOURSELF

3–5+ years · new hardware per pen & vial format · new patents and FDA filings.



PARTNER WITH VIVI

Available now · already patented & FDA-registered · 150,000+ devices already in market.

You don't need to build the injectable data layer — you need to partner with the one that already exists.

Every step up the mountain leads to one summit

A strategic partnership is where we are going. Portfolio, users, sales and profitability are how we climb there.



The partnership is the destination — portfolio, users, sales and profitability are how we make ourselves impossible to pass up.

Experts and users both highly recommend

HEALTHCARE PROFESSIONALS

“The VIVI Cap will be of particular benefit for my patients.”

Dr. W. Tamborlane · Chief of Pediatric Endocrinology, Yale University School of Medicine

“The VIVI Cap is an incredibly simple solution to ensure that insulin is safe.”

Dr. D. Isaacs · ADCES Diabetes Educator of the Year 2020

“I was so excited to find the VIVI Cap products. It’s a life-saving product.”

S. Sloane · Pharmacist, Diabetes Care and Education Specialist, Cleveland State University

Shared by hundreds of clinicians via FrontrowMD. Supported by Beyond Type 1 and the Diabetes Education & Camping Association.

REAL RESULTS LEAD TO HAPPY CUSTOMERS

4.4 ★★★★★¹/₂

645 Amazon ratings · VIVI Cap

50% of surveyed users already recommended VIVI Cap to a friend; a further 50% indicated they are likely to do so.

“It worked perfectly, even when I was out the entire day. Love it. Easy and efficient. I give it 5 stars.”

KATHY WESTLAKE · T1D FOR 20 YEARS

“I was skeptical... but it works and I absolutely love it!”

LIOR MANOR · T1D USER

“It’s convenient and compact... Highly recommended.”

LAURA CRAVEN · T1D USER

100,000+

TRUSTED USERS

4.8 / 5

AVERAGE RATING

50%

ALREADY RECOMMENDED

Experienced management team

**ILAN COHEN****Executive Chairman**

Serial entrepreneur and Former Director of the Israeli Prime Minister's office.

**RON NAGAR****Founder & CEO**

Medical device serial entrepreneur and inventor. Co-Founder InsuLine Medical and Glucon.

**GABI KABAZO****CFO**

20+ years of experience in accounting, finance and IT operations in complex corporate settings.

**DANIEL SALOMON****General Manager, America**

Ex Teva Executive, 17 years at Teva. Served as Head of Sales and Marketing for Teva USA institutional business unit.

**PROF. ANDREAS PFÜTZNER, M.D.****Medical Director**

Managing Director and Founder of PFÜTZNER Science & Health Institute GmbH, Germany.

**DR. TAMIR GEDO****Chairman, Advisory Board**

+25 years as a marketing and business strategy expert serving in academic, government, and industry functions

**JULIA BECKER****VP, Capital Markets**

15 years experience in capital markets, investor relations, and business development specializing in building strategic relationships.

**DAVID REID****Director of Manufacturing USA**

Manufacturing-focused executive with 30+ years of experience leading engineering, product development, & process automation across multiple industries.

Board / Advisors



SUSAN ALPERT, MD, PhD

Chief Regulatory Advisor

Former Director of Device Evaluation at the FDA, Senior VP Global Regulatory.



JULIA BECKER

Board of Directors

15 years experience in capital markets, investor relations, and business development.



JOHN SINCLAIR

Board of Directors

Senior business strategist and advisor, a CPA and CA with over 40 years of global experience.



BRIAN HOPKINS, JD

IP Counsel

US IP attorney with over 25 years of experience in intellectual property.



DR. DIANA ISAACS

Medical Advisor

Endocrine Clinical Pharmacist.
2020 ADCES Diabetes Care & Education Specialist of the Year.



Lutz Heinemann, PhD.

Scientific Advisory Board

A renowned expert in insulin pharmacology, diabetes technology, and temperature-sensitive medication stability .

Disclaimer

This Presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any security and may not be relied upon in connection with the purchase or sale of any security issued by the Company. Any such offer would only be made by means of definitive investment documents, the terms of which would govern in all respects.

You should not rely on the Presentation as the basis upon which to make any investment decision. This material does not purport to be all-inclusive or to contain all the information that a prospective investor may desire to consider in determining whether to make an investment. It is your obligation to conduct your own due diligence in making an investment decision. This material is provided for informational purposes only. To the extent that you rely on the Presentation in connection with any investment decision, you do so at your own risk. No person has been authorized to make any statement concerning the investment and any such statement, if made, may not be relied upon by you. Only those particular representations and warranties which may be made by the Company or its Officers in definitive investment documents, if and when they are executed, and subject to such limitations and restrictions as may be specified in such documents, may be relied upon and have any legal effect. Certain provisions of the investment documents are summarized in this Presentation, but you should not assume that the summaries are complete. Such summaries are qualified in their entirety by reference to the texts of the original documents.

The Presentation is not intended to provide, and should not be relied upon for, tax, legal, accounting or investment advice. You should consult your own attorneys, business advisers and tax advisers as to the investment and as to the tax, legal, accounting, business and other related matters. Any statements of federal tax consequences contained in the Presentation were not intended to be used and cannot be used to avoid penalties under the Internal Revenue Code or to promote, market or recommend to another party any tax related matters addressed herein. An investment in the Company involves risk of loss of all or part of your investment. Investors should have the financial ability and willingness to accept the risks associated with such investment.

Any projections or other estimates in this Presentation, including estimates of returns or performance, are forward-looking statements and are based upon certain assumptions. Other events, which were not taken into account, may occur and may significantly affect the outcome. Any assumptions should not be construed to be indicative of the actual events that will occur. Actual events are difficult to predict and may depend upon factors that are beyond the control of the Company or its Officers or Directors, and, accordingly, actual results will differ, and may differ significantly, from those presented. Certain information contained in the Presentation includes calculations or figures that have been prepared internally and have not been audited or verified by a third party. Use of different methods for preparing, calculating or presenting information may lead to different results, and such differences may be material.

Except where otherwise indicated, the information contained in the Presentation has been compiled as of September 2026 and none of the Company or its Officers or Directors has any obligation to update the Presentation. Under no circumstances should delivery of the Presentation create any implication that there have been no changes in the information contained in the Presentation since the date set forth above.

TempraMed

Ron Nagar

CHIEF EXECUTIVE OFFICER

ron@tempramed.com

www.tempramed.com

CSE: VIVI · OTCQB: TMPTF · FSE: 9DY